With improved market conditions, innovative breakthroughs, and more investor interest, the biotechnology industry is gaining new traction.

Investors’ deep pessimism is actually bullish, and less regulatory constraint could fuel new drug approvals and M&A.

Story March 5 - ALX Oncology: As the biotech looks to channel its cash into further trials of its CD47 blocker, the company will lay off 30% of its workforce. Story March 5 - Bristol Myers Squibb ...

J&J will now pick up almost the full tab for the phase 3 trial, and, in return, Nanobiotix will see the potential milestone ...

Sinovac Biotech (SVA) shareholder Heng Ren Partners ... s Board of Directors must take to create liquidity and release cash to shareholders. Specifically, Heng Ren demands that Sinovac’s ...

1. Small-cap and midcap (smid-cap) biotech stocks recently traded at an enterprise-value to cash ratio of 1.2, according to biotech analyst Michael Yee at Jefferies. Historically, this group ...